
Please try another search
Accenture Plc (NYSE:ACN) recently entered into a definitive agreement for the buyout of Rothco, an Irish creative agency based out of Dublin. This will mark the10th acquisition for Accenture this year and the 18th inorganic addition to its kitty in the last three years.
The terms of the acquisition were not disclosed and the deal is also subject to customary closing conditions. Rothco’s strategic planning and designing for impactful communications campaigns are expected to strengthen Accenture Interactive’s footprint in the UK and Ireland, thereby improving customer experience. Accenture also plans to expand Rothco’s presence internationally.
Rothco is also inclined toward enhancing the technological impact on creative procedure to optimize brand experience. Moreover, its impressive clientele that has the likes of Tesco (LON:TSCO) and Heineken is also anticipated to be beneficial for Accenture’s top line going ahead.
Accenture stock has gained 29.1% year to date, outperforming the 25.9% rally of the industry it belongs to.
Other Strategic Initiatives
Apart from acquisitions, Accenture’s strategic partnerships with companies like Google (NASDAQ:GOOGL), Microsoft (NASDAQ:MSFT) , Oracle (NYSE:ORCL) and Salesforce (NYSE:CRM) have also been key catalysts. Recently, the company entered into a partnership with Apple (NASDAQ:AAPL). These have helped the company in strengthening its product portfolio.
These partnerships have also helped the company to boost its presence across segments like IT security, customer relationship management and consulting, thereby enhancing its revenues. We expect the company to carry the momentum going forward backed by its sustained focus on operational efficiency.
Zacks Rank
Accenture has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Shares of Caesars Entertainment (NASDAQ:CZR), a leading gambling stock, traded around 3% higher on Wednesday morning, though the stock was trading around 1.5% lower shortly before...
Amazon (NASDAQ:AMZN) is making a significant push into the future with a robust investment in robotics and artificial intelligence. The company has earmarked $35 billion for...
Home Depot’s (NYSE:HD) Q4 2024 report and guidance for 2025 have plenty to be unhappy about, but the simple truth is that this company turned a corner in 2024. It is on track for...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.